Track record · closed signal

Gilead Sciences, Inc. (GILD) — closed signal from January 23, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 23, 2026.

Predicted vs. what happened

GILD price · publication thesis → realized outcomesplit-adjusted

$128.00 – $135.00Entry zone — fair-value band

$134.54Published — price the day we called it

$154.72Target — the price the thesis aimed for

$157.29Peak — highest point inside the window, not a realized return

$133.64Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 19 days.

Peak price

$157.29

peak on February 11, 2026 — not a realized return

Peak gain

+16.9%

peak, from the publication price

Window close

$133.64

end-of-window price, context only

Days to target

Window

January 23, 2026 – April 23, 2026

The thesis — published January 23, 2026

Predicted growth

+15%

over the measurement window

Target price

$154.72

the price the thesis aimed for

Entry zone

$128.00 – $135.00

the fair-value band we waited for

Price at publication

$134.54

published January 23, 2026

Confidence

72%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

The company just got a big, widely read clinical study result that makes its cancer treatment story more convincing. That news can make analysts and investors rethink value and keep interest high for weeks. The stock rose fast, so instead of buying now, wait for a dip and use tight risk limits in case people sell after the news.

Primary drivers

Major Phase 3 paper keeps the company in the news and draws analyst attention
Stronger combo-treatment data makes the cancer drug strategy more believable
Buying on pullbacks reduces paying too much after a fast jump
Healthcare shares can add variety if higher-growth stocks cool off

How it played out

GILD: target reached in 19 days

Lyra published GILD at $134.54 on 2026-01-23 with expected growth of 15%. The thesis pointed to a major Phase 3 paper, stronger combo-treatment data, buying on pullbacks after a fast rise, and healthcare exposure as a source of variety if higher-growth stocks cooled off.

Inside the 2026-01-23 to 2026-04-23 window, the stock reached $157.29 on 2026-02-11. That was above the $154.72 target, with a 16.9% peak gain, and it took 19 days. By the window end it was back at $133.64. The thesis played out, but the gain did not hold through the close.

What happened during the window

On 2026-02-11, Investor's Business Daily reported that Gilead had beaten fourth-quarter expectations and issued 2026 guidance. On 2026-04-07, The Wall Street Journal reported that Gilead agreed to buy Tubulis for $3.15 billion, with up to $1.85 billion in milestone payments.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All GILD signals